高级检索
当前位置: 首页 > 详情页

Evaluating the efficacy and safety of oral triple sequential combination therapy for treating patients with pulmonary arterial hypertension: A multicenter retrospective study

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Pulmonary Circulation, Shanghai Pulmonary Hospital Tongji University School of Medicine Shanghai China. [2]Department of Cardiology Xiamen Hospital of Traditional Chinese Medicine Fujian China. [3]Department of Cardiology, Tongji Hospital Tongji University School of Medicine Shanghai China. [4]Department of Cardiology Xuzhou Central Hospital Xuzhou China. [5]Department of Rheumatology, Renji Hospital Shanghai Jiaotong University School of Medicine Shanghai China. [6]Department of Cardiology First Affiliated Hospital of Nanjing Medical University Nanjing China. [7]Department of Cardiology and Atrial Fibrillation Center, The First Affiliated Hospital College of Medicine Zhejiang University Hangzhou Zhejiang China. [8]Department of Pulmonary and Critical Care Medicine, Sir Run Run Shaw Hospital Zhejiang University School of Medicine Hangzhou China. [9]Division of Life Sciences and Medicine, Department of Cardiology, The First Affiliated Hospital of USTC University of Science and Technology of China Hefei Anhui China. [10]Department of Cardiovascular Surgery, Fuwai Hospital Chinese Academy of Medical Sciences Guangdong Province Shenzhen China. [11]Department of Respiratory Medicine Zhongda Hospital of Southeast University Nanjing China.
出处:
ISSN:

关键词: event oral sequential triple combination therapy pulmonary arterial hypertension risk stratification survival

摘要:
This study aimed to evaluate the effectiveness and safety of an oral sequential triple combination therapy with selexipag after dual combination therapy with endothelin receptor antagonist (ERA) and phosphodiesterase-5 inhibitor (PDE5I)/riociguat in pulmonary arterial hypertension (PAH) patients. A total of 192 PAH patients from 10 centers had received oral sequential selexipag therapy after being on dual-combination therapy with ERA and PDE5i/riociguat for a minimum of 3 months. Clinical data were collected at baseline and after 6 months of treatment. The study analyzed the event-free survival at 6 months and all-cause death over 2 years. At baseline, the distribution of patients among the risk groups was as follows: 22 in the low-risk group, 35 in the intermediate-low-risk group, 91 in the intermediate-high-risk group, and 44 in the high-risk group. After 6 months of treatment, the oral sequential triple combination therapy resulted in reduced NT-proBNP levels (media from 1604 to 678 pg/mL), a decline in the percentage of WHO-FC III/IV (from 79.2% to 60.4%), an increased in the 6MWD (from 325 ± 147 to 378 ± 143 m) and a rise in the percentage of patients with three low-risk criteria (from 5.7% to 13.5%). Among the low-risk group, there was an improvement in the right heart remodeling, marked by a decrease in right atrium area and eccentricity index. The intermediate-low-risk group exhibited significant enhancements in WHO-FC and tricuspid annular plane systolic excursion. For those in the intermediate-high and high-risk groups, there were marked improvements in activity tolerance, as reflected by WHO-FC and 6MWD. The event-free survival rate at 6 months stood at 88%. Over the long-term follow-up, the survival rates at 1 and 2 years were 86.5% and 86.0%, respectively. In conclusion, the oral sequential triple combination therapy enhanced both exercise capacity and cardiac remodeling across PAH patients of different risk stratifications.© 2024 The Authors. Pulmonary Circulation published by John Wiley & Sons Ltd on behalf of Pulmonary Vascular Research Institute.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 4 区 医学
小类 | 4 区 心脏和心血管系统 4 区 呼吸系统
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 心脏和心血管系统 4 区 呼吸系统
JCR分区:
出版当年[2022]版:
Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Q3 RESPIRATORY SYSTEM
最新[2023]版:
Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Q3 RESPIRATORY SYSTEM

影响因子: 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者:
第一作者机构: [1]Department of Pulmonary Circulation, Shanghai Pulmonary Hospital Tongji University School of Medicine Shanghai China.
共同第一作者:
通讯作者:
通讯机构: [1]Department of Pulmonary Circulation, Shanghai Pulmonary Hospital Tongji University School of Medicine Shanghai China. [11]Department of Respiratory Medicine Zhongda Hospital of Southeast University Nanjing China. [*1]Department of Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China. [*2]Department of Respiratory Medicine, Zhongda Hospital of Southeast University, Nanjing 210009, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

相关文献

[1]Impact of different sequential triple oral combination therapies based selexipag on outcomes in pulmonary arterial hypertension [2]Radiomics-based survival risk stratification of glioblastoma is associated with different genome alteration [3]Upregulation of Piezo1 (Piezo Type Mechanosensitive Ion Channel Component 1) Enhances the Intracellular Free Calcium in Pulmonary Arterial Smooth Muscle Cells From Idiopathic Pulmonary Arterial Hypertension Patients. [4]Aloperine protects pulmonary hypertension via triggering PPARγ signaling and inhibiting calcium regulatory pathway in pulmonary arterial smooth muscle cells [5]Sildenafil for adult Asian patients with pulmonary arterial hypertension: a systematic review and meta-analysis. [6]Xinmai 'an extract enhances the efficacy of sildenafil in the treatment of pulmonary arterial hypertension via inhibiting MAPK signalling pathway. [7]Integrating Network Pharmacology and Experimental Verification to Explore the Pharmacological Mechanisms of Cordycepin against Pulmonary Arterial Hypertension in Rats [8]Chronic hypoxia promoted pulmonary arterial smooth muscle cells proliferation through upregulated calcium-sensing receptor-canonical transient receptor potential 1/6 pathway [9]3,7-Bis(2-hydroxyethyl)icaritin, a potent inhibitor of phosphodiesterase-5, prevents monocrotaline-induced pulmonary arterial hypertension via NO/cGMP activation in rats [10]Artificial intelligence in endoscopic ultrasonography: risk stratification of gastric gastrointestinal stromal tumors

资源点击量:2020 今日访问量:0 总访问量:646 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号